News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
BioSpace News Archive
Browse BioSpace’s published news and press releases by year, month, and day.
195 Results
Year
2005 (24679)
2006 (34770)
2007 (39687)
2008 (39410)
2009 (42118)
2010 (39616)
2011 (38383)
2012 (38416)
2013 (36268)
2014 (39672)
2015 (44431)
2016 (38329)
2017 (37187)
2018 (39119)
2019 (51334)
2020 (57662)
2021 (58720)
2022 (53927)
2023 (42564)
2024 (37440)
2025 (33091)
2026 (28450)
Month
January (2434)
February (2869)
March (3030)
April (3117)
May (3356)
June (2726)
July (2287)
August (2491)
September (2814)
October (3178)
November (148)
Day
1 (167)
2 (22)
3 (10)
4 (48)
5 (185)
6 (145)
7 (156)
8 (155)
9 (41)
12 (152)
13 (137)
14 (135)
15 (192)
16 (43)
18 (37)
19 (172)
20 (163)
21 (127)
22 (143)
23 (101)
25 (36)
26 (231)
27 (174)
28 (122)
29 (195)
30 (89)
Year
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Month
January
February
March
April
May
June
July
August
September
October
November
Day
1
2
3
4
5
6
7
8
9
12
13
14
15
16
18
19
20
21
22
23
25
26
27
28
29
30
Neuroscience
Ono cans 2 endocannabinoid drug studies after quintuple Phase 2 failure
Ono Pharma’s ONO-1110 failed five Phase 2 trials, leading to the discontinuation of development in depression and social anxiety. Work will continue for three pain indications.
October 29, 2026
·
1 min read
·
Annalee Armstrong
Press Releases
INmune Bio Inc. to Report Third Quarter 2026 Financial Results and Provide Corporate Update on Thursday, November 5th
October 29, 2026
·
4 min read
Press Releases
Mendoza Family Fund Surpasses $1 Million in Partnership with the National Multiple Sclerosis Society
October 29, 2026
·
3 min read
Press Releases
Tangram Announces First Participant Dosed in Phase 1 Trial of TGM-148, a Novel Investigational RNAi Medicine for Bleeding Disorders
October 29, 2026
·
4 min read
Press Releases
Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meeting
October 29, 2026
·
7 min read
Press Releases
Candel Therapeutics Announces Late-Breaking Abstract Accepted for Poster Presentation at the SITC 2026 Annual Meeting, Featuring Aglatimagene Besadenovec Data in Localized Prostate Cancer
October 29, 2026
·
6 min read
Press Releases
Exagen Inc. to Participate in Upcoming November 2026 Investor Conferences
October 29, 2026
·
1 min read
Press Releases
Artelo Biosciences to Present ART27.13 Data Demonstrating Potential to Treat Chemotherapy-Induced Neuropathic Pain at the IASP 2026 World Congress on Pain
October 29, 2026
·
6 min read
Press Releases
Precision Neuroscience Expands Clinical Network Beyond the U.S. with First International Site in Abu Dhabi
October 29, 2026
·
3 min read
Press Releases
Elicio Therapeutics to Present Phase 2 AMPLIFY-7P Results at the SITC 2026 Annual Meeting
October 29, 2026
·
7 min read
Previous
16 of 20
Next
